Rani Therapeutics Holdings (RANI) Capital Expenditures (2020 - 2026)
Rani Therapeutics Holdings (RANI) posted quarterly Capital Expenditures of $15000.0 for Q1 2026, down 70.59% year-over-year from $51000.0 in Q1 2025, and down 59.46% quarter-over-quarter from $37000.0 in Q2 2025.
Rani Therapeutics Holdings (RANI) Capital Expenditures (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Capital Expenditures history runs 7 years deep, the most recent figure standing at $15000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures fell 70.59% year-over-year to $15000.0; the TTM figure through Mar 2026 stood at $52000.0 (down 82.72% YoY), while the FY2025 annual figure was $88000.0, down 67.16% from the prior year.
- Capital Expenditures for Q1 2026 stood at $15000.0, down from $37000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $530000.0 in Q4 2022, with the low at -$333000.0 in Q3 2023.
- The 5-year median for Capital Expenditures is $85000.0 (2023), against an average of $133866.7.
- The sharpest annual moves came in 2022 and 2023: Capital Expenditures jumped 830.61% in 2022, then slumped 173.03% in 2023.
- Rani Therapeutics Holdings' Capital Expenditures stood at $530000.0 in 2022, then sank by 143.77% to -$232000.0 in 2023, then soared by 113.36% to $31000.0 in 2024, then climbed by 19.35% to $37000.0 in 2025, then tumbled by 59.46% to $15000.0 in 2026.
- Business Quant data shows RANI's Capital Expenditures at $15000.0 in Q1 2026, $37000.0 in Q2 2025, and $51000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 34.68 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.26 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 251.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -73.57 Mn |
| 10 | Rani Therapeutics Holdings | 160.33 Mn | 160.33 Mn | - | 32,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 32,000.00 |
| Jun 30, 2026 | 32,000.00 |
| Mar 31, 2026 | 15,000.00 |
| Mar 31, 2026 | 15,000.00 |
| Jun 30, 2025 | 37,000.00 |
| Jun 30, 2025 | 37,000.00 |
| Mar 31, 2025 | 51,000.00 |
| Mar 31, 2025 | 51,000.00 |
| Dec 31, 2024 | 31,000.00 |
| Dec 31, 2024 | 31,000.00 |
| Sep 30, 2024 | 125,000.00 |
| Sep 30, 2024 | 125,000.00 |
| Jun 30, 2024 | 94,000.00 |
| Jun 30, 2024 | 94,000.00 |
| Mar 31, 2024 | 18,000.00 |
| Mar 31, 2024 | 18,000.00 |
| Dec 31, 2023 | -232,000.00 |
| Dec 31, 2023 | -232,000.00 |
| Sep 30, 2023 | -333,000.00 |
| Sep 30, 2023 | -333,000.00 |